First line treatments post-cipriani Multiple treatments meta-analysis of antidepressants for major depression: strengths and weakness? by Cipriani, A

Prozac talks back by Cipriani, A

Time to abandon Evidence Based Medicine? by Cipriani, A

At what level of severity do we need antidepressive drugs? by Cipriani, A

Dataset for primary outcomes (Cipriani et al, Lancet 2016) by Cipriani, A

Other Authors: “…Cipriani, A…”

What have network meta-analyses taught us about treatment of mood disorders: is it time to revisit the hierarchy of evidence? by Cipriani, A

HOW IMPORTANT IS PLACEBO IN ANTIDEPRESSANT TRIALS? by Cipriani, A

Nulla dies sine linea by Cipriani, A

Advancing evidence-based practice to improve patient care. by Cipriani, A, Furukawa, T

Challenges in identifying behavioural markers of bipolar disorder through objective smartphone data by Goodday, S, Cipriani, A

Lessons learned from Restoring Study 329: transparent reporting, open databases and network meta-analyses as the way forward by Barber, S, Cipriani, A

Antidepressants in unipolar major depression: what we need to know by Barber, S, Cipriani, A

Antidepressants for bipolar disorder: A clinical overview of efficacy and safety by Cipriani, A, Geddes, J

Prophylactic mood stabilization: What is the evidence for lithium exposure in drinking water? by Awad, A, Cipriani, A

Predicting treatment outcome in depression: so far, so good. by Cipriani, A, Geddes, J

3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in service personnel by Cipriani, A, Cowen, P

Placebo for depression: we need to improve the quality of scientific information but also reject too simplistic approaches or ideological nihilism. by Cipriani, A, Geddes, J

Providing the most appropriate care to our individual patients by Cipriani, A, Tomlinson, A

Cluster randomised trials. by Barbui, C, Cipriani, A

The times they are a-changin' by Tomlinson, A, Cipriani, A